| Name | Title | Contact Details |
|---|
Codex DNA is home to Gibson Assembly, and pioneering synthetic DNA/gene synthesis hardware, including the BioXp, the world’s first DNA printer. Our mission is to empower scientific researchers in both academic and commercial settings with the materials...
Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases.
Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.
LabConnect is a global provider of clinical trial laboratory services, established in 2002 and based in Seattle, Washington. The company specializes in central laboratory solutions and functional service provider (FSP) support, partnering with pharmaceutical, biotechnology, and clinical research organizations. LabConnect has successfully managed over 1,900 clinical studies across 93 countries, emphasizing agility and innovation through a network of more than 30 laboratory locations worldwide. The company offers a range of services, including project management, a global testing network with over 10,000 validated tests, and comprehensive logistics and biorepository solutions. LabConnect also provides bioanalytical expertise and customized staffing for scientific project management. Its product offerings include customized lab kits for trial sites and integrated data management systems for real-time analytics. With a strong client portfolio that includes major pharmaceutical firms, LabConnect is positioned as a reliable partner for complex clinical trials.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.